Answers are grounded in this paper and cite their sources.
All patients had clinically significant improvements in PEE, and corneal sensation. Three of the four patients had a significant improvement in BCVA, one patient had no change in their pre-treatment visual acuity (BCVA 20/20) The four patients studied also reported decreased photophobia and improvements in their quality of life. This case series provides real-world evidence of the safety and efficacy of cenegermin treatment of stage I NK for all four patients.
No takes yet. Share an insight, caveat, or question.
Epitropoulos et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: